Grafa News and Videos — Page 359

GE Aerospace (NYSE:GE) agreed to acquire Consolidated Precision Products (CPP) for $11.75 billion, expanding its aerospace casting capabilities for commercial aviation, defense, and power markets.

AEVEX Corp. (NYSE:AVEX) completed its acquisition of BlackSea Technologies, adding unmanned surface and subsea vessel capabilities to its autonomous defense systems business.

Inhibrx Biosciences (NASDAQ:INBX) reported Phase 2 HexAgon trial results showing INBRX-106 combined with pembrolizumab achieved a 48.3% confirmed objective response rate in first-line head and neck cancer patients.

Abbott (NYSE:ABT) received U.S. FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, a device designed to treat atrial fibrillation using pulsed field ablation and radiofrequency energy technologies.

AstraZeneca (NASDAQ:AZN) reported Phase III OBERON and TITANIA trial results showing tozorakimab reduced moderate and severe COPD exacerbations across broad patient populations while patients remained on standard inhaled treatment.

enGene Therapeutics (NASDAQ:ENGN) reported regulatory and clinical progress for detalimogene, including plans for a U.S. FDA pre-BLA meeting and initiation of a Biologics License Application submission in the fourth quarter of 2026.

IonQ (NYSE:IONQ) expects full-year 2026 revenue of $450 million–$460 million following its acquisition of SkyWater Technology, with the outlook including SkyWater’s contribution from July 31 through December 31, 2026.

Adlai Nortye (NASDAQ:ANL) dosed the first patient in Australia in a global Phase I trial evaluating AN4035, an antibody-drug conjugate designed to treat CEACAM5-enriched RAS-addicted solid tumors.

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 2 QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel) in adults with quadruple-class exposed relapsed and refractory multiple myeloma.

United Natural Foods (NYSE:UNFI) reported fiscal 2026 net sales of $31.2 billion, down 2% year over year, while adjusted EBITDA increased 27% to $701 million.